К вопросу о новых терапевтических возможностях кисспептина

Вопросы оптимизации терапевтических возможностей в коррекции расстройств, связанных с нарушениями полового развития, репродуктивной системы, задержки старта пубертата, имеют высокую актуальность, так как в конечном счете данная группа патологий может негативно влиять на демографические показатели, связанные с рождаемостью, фертильностью и в целом с уровнем здоровья молодых людей. В настоящем обзоре представлены современные сведения о роли лиганд-рецепторной системы кисспептина KISS/KISS1R, открытие которой имело революционное значение для расшифровки генеза нейроэндокринной регуляции репродуктивной системы. Также приведен обзор и анализ исследований последних десятилетий о клинико-экспериментальных работах, направленных на изучение кисспептина и его агонистов как потенциальных терапевтических средств лечения ряда расстройств. Приведены данные о позитивном влиянии кисспептина на пульсаторную секрецию ГнРГ и гонадотропинов, что может быть использовано в лечении гипогонадотропного гипогонадизма, нарушений овуляции и других болезней репродуктивной системы. Также освещены данные о возможностях применения кисспептина в коррекции связанной с ожирением неалкогольной жировой болезни печени, остеопенических состояний, психосексуальных расстройств. Разработка аналогов кисспептина потенциально может решить некоторые фармакологические проблемы, возникающие при использовании природных форм кисспептина, хотя для реализации этого потенциала необходимы дальнейшие клинические испытания.

1. Parent A-S, Teilmann G, Juul A, et al. The Timing of Normal Puberty and the Age Limits of Sexual Precocity: Variations around the World, Secular Trends, and Changes after Migration. Endocrin Reviews. 2003;24(5):668–693.

2. Дедов И.И., Петеркова В.А. Детская эндокринология. М.: Универсум Паблишинг, 2006. 600 с.

3. Никитина И.Л. Детская эндокринология. Ростов-на Дону: Феникс, 2006. 224 с.

4. Abreu AP, Kaiser UB. Pubertal development and regulation. Lancet Diabetes Endocrinol. 2016; 4(3): 254– 264. DOI: 10.1016/S2213-8587(15)00418-0.

5. Ojeda SR, Lomniczi A, Sandau U, et al. New concepts on the control of the onset of puberty. In Loche S, Cappa M, Ghizzoni L, et al. Pediatric Neuroendocrinology: Endocr Dev. Basel, Karger. 2010. Vol. 17. P. 44–51.

6. Lomniczi A, Ojeda SR. The emerging role of epigenetics in the regulation of female puberty: in Bourguignon J-P, Parent A-S (eds): Puberty from bench to clinic. Lessons for clinical management of pubertal disorders. Endocr Dev. Basel, Karger. 2016. Vol. 29. P. 1–16.

7. Willemsen RH, Dunger DB. Normal variations in pubertal timing: genetic determinants in relation to growth and adiposity: in Bourguignon J-P, Parent A-S (eds): Puberty from bench to clinic. Lessons for clinical management of pubertal disorders. Endocr Dev. Basel, Karger. 2016. Vol. 29. P. 17–35.

8. Bourguignon J-P, Parent A-S, Mullis PE. Puberty from Bench to Clinic. 1st edition. Karger. 2016. 263 p.

9. De Roux N, Genin E, Carel JC, et al. Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54. Proc Natl Acad Sci U S A. 2003; 100(19):10972–6. DOI: 10.1073/pnas.1834399100.

10. Tsoutsouki J, Abbara A, Dhillo W. Novel therapeutic avenues for kisspeptin. Current Opinion in Pharmacology. 2022; 67:102319. doi.org/10.1016/j.coph.2022.102319.

11. Mills EG, Yang L, Abbara A, et al. Current perspectives on kisspeptins role in behaviour. Front Endocrinol (Lausanne). 2022; 13: 928143.

12. Comninos AN, Hansen MS, Courtney A, et al. Acute effects of kisspeptin administration on bone metabolism in healthy men. J Clin Endocrinol Metab. 2022, 107:1529–1540, https://doi.org/10.1210/clinem/dgac117.

13. Guzman S, Dragan M, Kwon H, et al. Targeting hepatic kisspeptin receptor ameliorates nonalcoholic fatty liver disease in a mouse model. J Clin Invest. 2022 May 16;132(10):e145889.

14. Tsoutsouki J, Patel B, Comninos AN, et al. Kisspeptin in the prediction of pregnancy complications. Front Endocrinol. (Lausanne). 2022; 13: 942664. doi.org/10.3389/fendo.2022.942664.

15. Scott G, Ahmad I, Howard K, et al. Double-blind, randomized, placebo-controlled study of safety, tolerability, pharmacokinetics and pharmacodynamics of TAK-683, an investigational metastin analogue in healthy men. Br J Clin Pharmacol. 2013; 75(2): 381–91 DOI: 10.1111/j.1365-2125.2012.04385.x.

16. Abbara A, Eng PC, Phylactou M, et al. Kisspeptin receptor agonist has therapeutic potential for female reproductive disorders. J Clin Invest. 2020; 130:6739–6753. DOI: 10.1172/JCI139681.

17. Abbara A, Clarke SA, Dhillo WS. Clinical potential of kisspeptin in reproductive health. Trends Mol Med. 2021; 27:807–823.

18. Dhillo WS, Chaudhri OB, Patterson M, et al. Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males. J Clin Endocrinol Metab. 2005; Dec, 90:6609–6615.

19. Chan Y-M, Butler JP, Pinnell NE, et al. Kisspeptin resets the hypothalamic GnRH clock in men. J Clin Endocrinol Metab. 2011 Jun;96(6):E908–15.

20. George JT, Veldhuis JD, Roseweir AK, et al. Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men. J Clin Endocrinol Metab. 2011 Aug;96(8):E1228–36. DOI: 10.1210/jc.2011-0089.

21. Dhillo WS, Chaudhri OB, Thompson EL, et al. Kisspeptin-54 stimulates gonadotropin release most potently during the preovulatory phase of the menstrual cycle in women. J Clin Endocrinol Metab. 2007; 92:3958–3966.

22. Mills EG, Swedrowska M, Thurston L, et al. Intranasal kisspeptin administration stimulates reproductive hormone secretion in healthy men [cited 2022 Aug 12] Endocr Abstr. 2021 Oct 18:77.

23. Jayasena CN, Nijher GMK, Abbara A, et al. Twice-weekly administration of kisspeptin-54 for 8 weeks stimulates release of reproductive hormones in women with hypothalamic amenorrhea. Clin Pharmacol Ther. 2010; 88:840–847.

24. Jayasena CN, Nijher GMK, Chaudhri OB, et al. Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxis. J Clin Endocrinol Metab. 2009; 94: 4315–4323.

25. Jayasena CN, Nijher GMK, Comninos AN, et al. The effects of kisspeptin-10 on reproductive hormone release show sexual dimorphism in humans. Available from: https://academic.oup.com/jcem/article/96/12/E1963/2834843.

26. Jayasena CN, Comninos AN, Veldhuis JD, et al. A single injection of kisspeptin-54 temporarily increases luteinizing hormone pulsatility in healthy women [cited 2022 Jun 20] Clin Endocrinol. 2013; 79:558–563.

27. Jayasena CN, Nijher GMK, Comninos AN, et al. The effects of kisspeptin-10 on reproductive hormone release show sexual dimorphism in humans. J Clin Endocrinol Metab. 2011; 96:E1963–E72.

28. Chan Y-M, Butler JP, Sidhoum VF, et al. Kisspeptin administration to women: a window into endogenous kisspeptin secretion and GnRH responsiveness across the menstrual cycle. E1458 jcem.endojournals.org J Clin Endocrinol Metab. 2012; 97.

29. George JT, Veldhuis JD, Tena-Sempere M, et al. Exploring the pathophysiology of hypogonadism in men with type 2 diabetes: kisspeptin-10 stimulates serum testosterone and LH secretion in men with type 2 diabetes and mild biochemical hypogonadism. Clin Endocrinol. 2013; 79:100–104.

30. Abbara A, Narayanaswamy S, Izzi-Engbeaya C, et al. Hypothalamic response to kisspeptin-54 and pituitary response to gonadotropinreleasing hormone are preserved in healthy older men. Neuroendocrinology. 2018; 106:401–410.

31. Matsui H, Masaki T, Akinaga Y, et al. Pharmacologic profiles of investigational kisspeptin/metastin analogues, TAK-448 and TAK-683, in adult male rats in comparison to the GnRH analogue leuprolide. Eur J Pharmacol. 2014; 735:77–85.

32. Gordon CM, Ackerman KE, Berga SL, et al. Functional hypothalamic amenorrhea: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2017;102:1413–1439.

33. Abbara A, Islam R, Clarke SA, et al. Clinical parameters of ovarian hyperstimulation syndrome following different hormonal triggers of oocyte maturation in IVF treatment. Clin Endocrinol. 2018;88:920–927.

34. Jayasena CN, Abbara A, Comninos AN, et al. Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization. J Clin Invest. 2014; 124:3667–3677.

35. Abbara A, Jayasena CN, Christopoulos G, et al. Efficacy of kisspeptin-54 to trigger Oocyte maturation in women at high risk of ovarian hyperstimulation syndrome (OHSS) during in vitro fertilization (IVF) therapy. J Clin Endocrinol Metab. 2015;100: 3322–3331.

36. Abbara A, Clarke S, Islam R, et al. A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome: a Phase 2 randomizedcontrolled trial. Hum Reprod. 2017;32:1915–1924.

37. Abbara A, Hunjan T, Ho VNA, et al. Endocrine requirements for oocyte maturation following hCG, GnRH agonist, and kisspeptin during IVF. In Treatment. Lausanne: Front Endocrinol. 2020 Oct 6:11.

38. Abbara A, Clarke SA, Dhillo WS. Novel concepts for inducing final oocyte maturation in in vitro fertilization treatment. Endocr Rev 2018 Oct, 39:593–628.

39. Jayasena CN, Abbara A, Veldhuis JD, et al. Increasing LH pulsatility in women with hypothalamic amenorrhoea using intravenous infusion of kisspeptin-54. J Clin Endocrinol Metab. 2014; 99:E953–E961.

40. Castellano JM, Navarro VM, FernándezFernández R, et al. Changes in hypothalamic KiSS-1 system and restoration of pubertal activation of the reproductive axis by kisspeptin in undernutrition. Endocrinology. 2005;146:3917–3925.

41. Chan Y-M, Lippincott MF, Kusa TO, et al. Divergent responses to kisspeptin in children with delayed puberty. JCI Insight. 2018;19;3(8):e99109. DOI: 10.1172/jci.insight.99109.

42. Chan Y-M, Lippincott MF, Barroso PS, et al. Using Kisspeptin to Predict Pubertal Outcomes for Youth With Pubertal Delay. J Clin Endocrinol Metab. 2020;105(8):e2717–e2725. DOI: 10.1210/clinem/dgaa162.

43. Никитина И.Л. Ожирение у детей и подростков: проблема, пути решения. Обзор российских и международных рекомендаций. Лечащий врач. 2018;1: 31–36.

44. Mills EG, Yang L, Abbara A, et al. Current perspectives on kisspeptins role in behaviour. Front Endocrinol (Lausanne). 2022;13. https://doi.org/10.3389/fendo.2022.928143.

45. Yang L, Demetriou L, Wall MB, et al. Kisspeptin enhances brain responses to olfactory and visual cues of attraction in men. JCI Insight. 2020; 5. https://doi.org/10.1172/jci.insight.133633.

46. Comninos AN, Wall MB, Demetriou L, et al. Kisspeptin modulates sexual and emotional brain processing in humans. J Clin Invest. 2017 Feb 1, 127:709–719, https://doi.org/10.1172/JCI89519.

47. Wang F-S, Chen H, Wu Z-Y, et al. KISS1 expression in osteosarcoma: high in Chinese clinical cases, but lower in cell lines. Asian Pac J Cancer Prev APJCP. 2011; 12:3229–3234.

48. Dotterweich J, Tower RJ, Brandl A, et al. The KISS1 receptor as an in vivo microenvironment imaging biomarker of multiple myeloma bone disease. PLoS One. 2016 May 9;11(5):e0155087.

49. de Sousa IO, Diniz ET, Marques TF, et al. Shortterm bone marker responses to teriparatideand strontium ranelate in patients with osteoporosis previously treated with bisphosphonates. Arq Bras Endocrinol Metabol. 2010; 54:244–249.